FindTrial
Sign In

AZD5335

DRUG4 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

Advanced Platinum-resistant Epithelial Ovarian CancerEndometrial CancerEpithelial Ovarian CancerFallopian Tube CancerLung AdenocarcinomaOvarian CancerPrimary Peritoneal

Phase 1

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RecruitingNCT05797168
AstraZenecaEndometrial Cancer, Lung Adenocarcinoma, Ovarian Cancer
Start: 2023-06-05End: 2028-01-06Target: 506Updated: 2026-03-02
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
RecruitingNCT07402915
AstraZenecaFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal
Start: 2026-01-26End: 2027-10-15Target: 24Updated: 2026-04-02

Phase 3

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
RecruitingNCT07218809
AstraZenecaEpithelial Ovarian Cancer
Start: 2025-12-29End: 2030-05-27Target: 1100Updated: 2026-01-16
Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
Not yet recruitingCTIS2025-520466-22-00
AstraZeneca ABAdvanced Platinum-resistant Epithelial Ovarian Cancer
Target: 46Updated: 2026-03-27

Related Papers

Abstract LB406: Synergistic antitumor effect of FRα TOP1i antibody drug conjugate, AZD5335, in combination with the PARP1 inhibitor, saruparib (AZD5305), in preclinical models of ovarian cancer
Cancer Research2024-04-05
Modulatory Potential of Poly (ADP‐Ribose) Polymerase 1 (PARP1) in BRCA‐Mutated Tumors
European Journal of Cancer Care2024-01-011 citations